Xtandi Still Faces Likely US Price Cut Even As It Avoids ‘March In’ Proceeding
Executive Summary
The Biden administration decision not to pursue ‘march in’ proceedings for Pfizer/Astellas’ Xtandi sounds like good news. The reality is that the prostate cancer therapy is likely to face a more certain federal pricing intervention in the first year of the new Medicare ‘negotiation’ process.
You may also be interested in...
Biden's Latest Rx Pricing Moves Are At Once Bold And Incremental
As the president’s reelection campaign themes take shape, the administration is preparing to leverage NIH patents in ways it had previously eschewed. As with the merger oversight effort, though, the germs of the plans began earlier in Biden’s tenure.
Biden's Latest Rx Pricing Moves Are At Once Bold And Incremental
As the president’s reelection campaign themes take shape, the administration is preparing to leverage NIH patents in ways it had previously eschewed. As with the merger oversight effort, though, the germs of the plans began earlier in Biden’s tenure.
Novo Nordisk’s Wegovy In Medicare Part D: Coverage May Not Be The Only Problem
Prospect of facing price negotiation in Part D may lead Novo Nordisk to consider earlier-than-currently-planned generic competition for its older semaglutide drug for diabetes, Ozempic.